Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In Q4, we continue to see positive momentum in the business, both financially and operationally |
| And - they don't - they needed time to bake into our financial results, and I'm encouraged by the fact that now you're seeing the visible signs of progress that's a return to growth not just on the top line, but obviously, nice incremental scaling profitably, to the bottom line |
| Consistent with the preliminary Q4 results we announced in January, our Q4 year-over-year adjusted revenue growth accelerated to 7% up significantly compared to our Q3 growth rate, and our Q4 adjusted EBITDA margin was 29.1%, up 220 basis points year-over-year, with adjusted EBITDA growing 15% year-over-year |
| We believe these market coverage trends are stronger than they've ever been, and we don't expect them to change |
| We are pleased to see that as a really a reflection of the relationships we have, and the value we add when we deliver prescriptions to our customers, our PBMs and our pharmacies |
| So, we're a pretty high return marketing vehicle in pharma, and one that I would say is pretty unique and extremely valuable |
| We believe the market tailwinds are increasing, patient out-of-pocket costs are growing |
| We should be able to outperform a market that grows in the mid-single digit simply by penetrating more brands that we think have high value with us, and the work we're doing is really getting ourselves in front of brand managers, access teams, and agencies, which, are different in every single company, but getting our value prop for the right things in front of them, and having them sign up and run programs |
| Our own gold users are growing, which we talked about in our prepared remarks, and we're quite pleased with that, because it does reflect the value proposition that we offer to them, and their interest in it, which is something we're very pleased with |
| Our financial results continue to improve as we focus on helping our industry partners in the value chain, benefit proportionally from the value that GoodRx creates for our 25 million-plus consumers annually |
| Critically, we believe that our retail direct contracting strategy, which takes a cost aligned approach positions us well for sustainable growth in a market with evolving pharmacy reimbursement models |
| The early traction we're seeing for ISP so far in 2024 is encouraging and its contribution to Q1 revenue is reflected in our growth expectations |
| Our users, our HCP advocacy are growing too, making us confident in the strength of the GoodRx value proposition and our ability to grow our business |
| So I think, first of all, we've been really pleased with the performance of our tech teams |
| Along with increasing lives, we believe we can inflect conversion as well, given we've historically been able to increase GoodRx discounts and lower pricing over time in our non-ISP, direct-to-consumer offerings |
| I will say I'm confident our priorities are the right ones to deliver the growth we're expecting in 2024 and to drive shareholder value over the long term |
| Considering that, we're pleased with our anticipated 2024 Pharma Manufacturer Solutions growth |
| And if we're successful in driving more types of transactions, and more lives to the program as we help drive more employer sales, we may achieve incremental lift in the coming months and during 2025's patient deductible reset period |
| Adjusted EBITDA margin was up 220 basis points year-over-year to approximately 29.1%, which was on the high end of our guidance range |
| The primary driver of the year-over-year increase was higher adjusted revenue, along with our cost discipline, increased marketing efficiency and the actions taken to restructure pharma manufacturer solutions, including the deprioritization of vitaCare |
| Prescription transactions revenue grew 11% year-over-year to $143.9 million, an acceleration from Q3 growth which was partially driven by quarter-specific favorability related to certain client contracts, which also slightly increased PTR per MAC |
| In summary, during the fourth quarter, adjusted revenue exceeded the guidance range we provided on our Q3 earnings call in November and adjusted EBITDA margin was in the upper end of the guidance range we provided |
| But given our scale relative to very large TAMs for a prescription marketplace and our pharma manufacturer solutions offering, we're confident in the growth trajectory |
| And so now, right now, you're basically just seeing the GoodRx operating in the way that we can within the system |
| Total revenue and adjusted revenue for the quarter increased 7% year-over-year to $196.6 million primarily driven by organic growth in prescription transactions revenue |
| And also want to make sure it's a good experience for our shared customers, their retail customers and ours |
| And the number of things that we have underway, the nice thing is, if we keep landing them, we should be able to continue, to drive that growth above category rates |
| We've been leaning into our access and awareness solutions that we believe will accelerate 2024 growth |
| So, I think the first point to make, is ISP is up about 2x year-over-year, which we're pretty pleased with |
| Because it'll be good for the system, and it'll also be good for us |
| Statement |
|---|
| For those who have been following both GoodRx and the industry in recent years, short-term movements in the industry value chain have created some confusion about our prospects |
| As a reminder, our Pharma Manufacturer Solutions offering has some seasonality to it and so we expect 1Q '24 revenue to be slightly below 4Q '23 revenue |
| Subscriptions revenue declined 6% to $23.1 million due to the wind down of Kroger Savings Club |
| Pharma Manufacturer Solutions declined 2% year-over-year to $24.4 million driven by our restructuring of the offering, which included shutting down vitaCare |
| Kroger Savings Club revenue was over $1 million less in the fourth quarter of 2023 than in the prior year period |
| The anticipated adjusted revenue growth rate is tempered by approximately $15 million of top line impact associated with the deprioritization of vitaCare as part of our pharma manufacturer solutions restructuring as well as the wind down of the Kroger Savings Club |
| That's one of the big reasons we refer, to this as being an issue that affected us, for a couple of days versus an issue that, affected many in the industry for a longer period of time |
| Can you elaborate more on the dependencies and integration there? Is it more for your pharmacy partners, more on the PBM side? I know you said two days, but it seems systems were down longer than that, have been down longer than that |
| On direct contracting, you've previously noted that it might be a slight headwind to PTR per MAC, just given those contracts generally have lower admin fees |
| But that's all sort of, below the revenue line for the most part |
| Net loss was $25.9 million compared to a net loss of $2.0 million in the fourth quarter of 2022 |
| So if you compare that, they're about one-sixth as valuable, right? So as Kroger Savings Club rolls off, we will see subscription - subscriber counts decrease, but the revenue impact is much, much more diminished |
| Factors discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2023, and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made on this call |
| I feel there's a lot of questions on the cost-plus model that's been floated about CVS and Walgreens |
| Consumers today are facing rising healthcare costs with plans continuing to increase patient out-of-pocket costs, like deductibles and co-pays and increasing gaps of drug coverage with narrower formularies |
| Scott, I had a question about what I think about is like tail risk |
Please consider a small donation if you think this website provides you with relevant information